Clinical trial
A Phase 2B Efficacy and Safety Study of PTC124 in Subjects With Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy
NCT00592553 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2B Efficacy and Safety Study of PTC124 in Subjects With Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy
- Lead sponsor
- PTC Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 29, 2008
- Completion date
- December 31, 2009
- Enrollment
- 174 (actual)
- Sites
- 37
Conditions
As the registry lists them; a condition with its own page is linked.
becker muscular dystrophy, duchenne muscular dystrophy